Synthetic Biologics

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:acquisition various biotech firms
gptkbp:awards biotech innovation awards
gptkbp:ceo Steven A. Shallcross
gptkbp:clinical_trial Phase 1
clinical trials
Phase 2
patient-centered approaches
various drug candidates
gptkbp:collaborations academic institutions
multidisciplinary teams
biopharmaceutical companies
gptkbp:community_engagement healthcare initiatives
gptkbp:conference biotechnology conferences
gptkbp:focus microbiome therapeutics
developing therapeutics for microbiome-related diseases
gptkbp:focus_area antibiotic resistance
gastrointestinal diseases
immune system modulation
gptkbp:founded gptkb:2012
gptkbp:headquarters gptkb:Rockville,_Maryland
https://www.w3.org/2000/01/rdf-schema#label Synthetic Biologics
gptkbp:invention various biotechnology patents
gptkbp:investment institutional investors
public offerings
gptkbp:language_of_instruction multiple drug candidates
gptkbp:leadership experienced biotech executives
gptkbp:mission improve patient outcomes
gptkbp:notable_products gptkb:SYN-004
SYN-005
SYN-010
gptkbp:partnerships various pharmaceutical companies
gptkbp:publishes gptkb:academic_journal
gptkbp:receives_funding_from gptkb:Company
gptkbp:regulatory_compliance FDA approval process
gptkbp:research_areas gptkb:item
gptkbp:social_responsibility sustainable practices
gptkbp:staff experts in microbiome research
gptkbp:strategic_importance improve operational efficiency
foster innovation
advance scientific knowledge
enhance research capabilities
strengthen partnerships
expand product pipeline
increase market presence
support patient advocacy
gptkbp:technology data analytics
bioinformatics
genetic engineering
biomanufacturing
cellular engineering
gptkbp:traded_on gptkb:NYSE_American
gptkbp:vision transforming medicine through synthetic biology
gptkbp:website www.syntheticbiologics.com
gptkbp:bfsParent gptkb:SYN-004
gptkbp:bfsLayer 6